  Antimicrobial resistance is a silent pandemic that is being exacerbated by
the uncontrolled use of antibiotics. Since the discovery of penicillin, we have
been largely dependent on microbe-derived small molecules to treat bacterial
infections. However, the golden era of antibiotics is coming to an end as the
emergence and spread of antimicrobial resistance against these antibacterial
compounds is outpacing the discovery and development of new antibiotics. The
current antibiotic market suffers from various shortcomings, including the
absence of profitability and investment. However, the most important underlying
issue of traditional antibiotics arises from the inherent properties of these
small molecules being mostly broad-spectrum and non-programmable. As the
scientific knowledge of microbes progresses, the scientific community is
starting to explore entirely novel approaches to tackling antimicrobial
resistance. One of the most prominent approaches is to develop next-generation
antibiotics. In this review, we discuss three innovations of next-generation
antibiotics compared to traditional antibiotics as specificity, evolvability,
and non-immunogenicity. We present a number of potential antimicrobial agents,
including bacteriophage-based therapy, CRISPR-Cas-based antimicrobials, and
microbiome-derived antimicrobial compounds. These alternative antimicrobial
agents possess innovative properties that may overcome the inherent
shortcomings of traditional antibiotics, and some of these next-generation
antibiotics are not merely far-fetched ideas but are currently in clinical
development. We further discuss some related issues and challenges such as
infection diagnostics and regulatory frameworks that still need to be addressed
to bring these next-generation antibiotics to the antibiotic market as viable
products to combat antimicrobial resistance using a diversified set of
strategies.
